Engineered immune cells take on stomach cancer in new trial

NCT ID NCT07179484

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1b trial is testing a personalized cell therapy called CT041 CAR-T for people with advanced stomach or gastroesophageal junction cancer. After completing standard first-line treatment, 20 participants will receive up to three infusions of their own engineered immune cells. The goal is to see if this approach can delay cancer progression and improve survival, while monitoring safety and how the cells behave in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CT041 autologous CAR-T cell injection
What this could lead to: If successful, this could offer a new treatment option to control advanced gastric cancer after initial therapy, potentially extending time without disease progression.
What could go wrong: This is a small, early-phase trial (20 participants) focused on safety and dosing, so results may not confirm effectiveness. CAR-T therapy carries risks like cytokine release syndrome and neurological side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

BeijingGoBroadH
RECRUITING

Beijing, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.